Clinical Trial Update: Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting safety and immune response data for a live-attenuated Respiratory Syncytial Virus vaccine in RSV-seronegative infants and childre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV Live-Attenuated Vaccine (live-attenuated Respiratory Syncytial Virus vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED